Skip to content

Another vaccine manufacturer in the case

  • Novavax (NVAX) has already started the development of a new recombinant peak protein based on the known genetic sequence of the new variant.
  • They believe their vaccine is likely to provide protection against the new variant.
  • will have a new recombinant spike proton based on a known genetic sequence from a new variant ready to be tested and manufactured in the next few weeks

JnJ, AstraZeneca is already on the case. Now Novavax joins the fight.

Invest in yourself. See our forex education center.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.